To whom it may concern,

6876 '01 MAR 27 P4:27

I am writing concerning Docket # 00N-0989 involving clinical trials of either gene therapy or xenotransplantation.

This proposal only brings gene therapy and xenotransplantation in compliance with the same types of information already released to the public by other government agencies. Because of grave public health risks, disclosure should include additional information such as physicians, medical centers and so on - make public all information except trade secrets and patient identification.

The FDA must assume the sole responsibility for summarizing and distributing information submitted by the research sponsor, rather than leave it to the sponsor's discretion.

Because of the public health risks, ethical issues, cost uncertainy, and the inability to adequately assess other alternatives, all xeno-transplantation clinical trials should stop.

Sincerely,

D. Nuzzo
81 E. Main St.
Branford, CT.
06405

00N-0989 C34

SOUTHERN CT 06490
PM
22 MAR
2001

U.S. Food + Drug Administration
Dockets Management Branch
Docket # 00N-0989
5630 Fisher's Lane Room 1061
Rockville, Md. 20852